2-(2fluorophenyl)benzylacetic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(2fluorophenyl)benzylacetic acid
• 英文别名: 3-[2-(2-Fluorophenyl)phenyl]propanoic acid
• 化学式: C₁₅H₁₃FO₂
• 分子量: 244.265
• InChiKey: OMLJHSHJNGEQMU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(2fluorophenyl)benzylacetic acid 在 lithium aluminium tetrahydride 、 1-羟基苯并三唑一水物 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.5h， 生成 (+/-)-1-[3-(20-Fluorobiphenyl-2-yl)propyl]-4-[2-(4-fluorophenyl)-2-(1-isopropylpiperidin-4-yl)ethyl]piperazinetri hydrochloride
  参考文献：
  名称：

  Novel piperazines: Potent melanocortin-4 receptor antagonists with anxiolytic-like activity

  摘要：

  In the present study, we found that a novel piperazine compound, 11a, showed a moderate affinity (IC50 = 333 nM) for the MC4 receptor. We developed the new type of piperazine compounds and found that mono-piperazine 11b exhibited a high-affinity (IC50 = 40.3 nM) for the MC4 receptor. We also found that a series of biphenyl analogues exhibited a high-affinity for the receptor, and in particular, compound 11j exhibited the highest affinity for the MC4 receptor with an IC50 value of 14.5 nM. Further-more, some of these compounds, when administered orally, significantly reversed the stress-induced anxiety-like behavior in rats. In this paper, we report the synthesis, structure-activity relationships, and oral activity of the novel mono-piperazines as MC4 receptor antagonists. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.01.019

文献信息

• Tetracyclic compounds
  申请人：Kyowa Hakko Kogyo Co., Ltd.

  公开号：US05371225A1

  公开（公告）日：1994-12-06

  The present invention relates to novel tetracyclic compounds represented by formula (I) ##STR1## (wherein each of X.sup.1 and X.sup.2 independently represents hydrogen or lower alkyl; n represents an integer of 1 to 4), or a pharmaceutically acceptable salt thereof, which are useful as immunosuppressive agents.

  本发明涉及一种新型四环化合物，其化学式表示为（I）##STR1##（其中X.sup.1和X.sup.2各自独立地代表氢或较低的烷基；n代表1至4的整数），或其药学上可接受的盐，其作为免疫抑制剂具有用途。
• 2-ARYL-ZINC-PROPIONATE CATALYST AND PREPARATION METHOD AND USE THEREOF
  申请人：FUDAN UNIVERSITY

  公开号：US20160326085A1

  公开（公告）日：2016-11-10

  The present invention belongs to the technical field of chemical catalysts, and particularly relates to a zinc 2-arylpropionate catalyst, a preparation method therefor and use thereof The structural formula of the zinc 2-arylpropionate catalyst of the present invention is one of the following structures. The catalyst can be used for homogeneous catalysis of a 1,2-aryl rearrangement reaction of α-haloarylketal, and especially for synthesis of high yield and environmentally friendly 2-arylpropanonic acid non-steroidal anti-inflammatory analgesic drugs, such as, ibuprofen, ketoprofen, loxoprofen, flurbiprofen, fenoprofen, or naproxen and the like.

  本发明属于化学催化剂技术领域，特别涉及一种锌2-芳基丙酸盐催化剂，其制备方法及用途。本发明的锌2-芳基丙酸盐催化剂的结构式为以下结构之一。该催化剂可用于α-卤芳基醚的1,2-芳基重排反应的均相催化，特别适用于合成高产率、环境友好的2-芳基丙酸非甾体抗炎镇痛药物，例如布洛芬、肯洛布芬、洛索洛芬、氟比洛芬、芬普芬或萘普生等。
• [EN] PROCESS FOR PREPARING OPTICALLY ACTIVE CARBOXYLIC ACIDS<br/>[FR] PROCEDE POUR PREPARER DES ACIDES CARBOXYLIQUES OPTIQUEMENT ACTIFS
  申请人：UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION

  公开号：WO1997014669A1

  公开（公告）日：1997-04-24

  (EN) This invention relates to a process for preparing optically active carboxylic acids by oxidizing an optically active aldehyde with a peracid in the presence of an amine and/or amine N-oxide catalyst selected from the group consisting of a substituted or unsubstituted alkyl amine, alkyl amine N-oxide, aromatic amine, aromatic amine N-oxide, heterocyclic amine, heterocyclic amine N-oxide and mixtures thereof, to produce the optically active carboxylic acid. Such optically active carboxylic acids have utility for example as pharmaceuticals.(FR) La présente invention concerne un procédé pour préparer des acides carboxyliques optiquement actifs par oxydation d'un aldéhyde optiquement actif avec un peracide en présence d'une amine et/ou d'un catalyseur au N-oxyde d'amine choisi dans le groupe composé d'une alkylamine substituée ou non substituée, d'un N-oxyde d'alkylamine, d'une amine aromatique, d'un N-oxyde d'amine aromatique, d'une amine hétérocyclique, d'un N-oxyde d'amine hétérocyclique et de leurs mélanges, en vue de produire l'acide carboxylique optiquement actif. De tels acides carboxyliques optiquement actifs sont utiles par exemple comme produits pharmaceutiques.

  该发明涉及一种制备光学活性羧酸的方法，其中在氨和/或氨N-氧化物催化剂的存在下，使用过氧酸对光学活性醛进行氧化，所述催化剂被选择自取代或未取代的烷基胺，烷基胺N-氧化物，芳香胺，芳香胺N-氧化物，杂环胺，杂环胺N-氧化物和它们的混合物，从而产生光学活性羧酸。这种光学活性羧酸例如可用作制药的用途。
• NOVEL TETRACYCLIC COMPOUND
  申请人：KYOWA HAKKO KOGYO KABUSHIKI KAISHA

  公开号：EP0601191A1

  公开（公告）日：1994-06-15

  A novel tetracyclic compound useful as an immuno-suppressant, represented by general formula (I), or a pharmacologically acceptable salt thereof wherein X¹ and X² may be the same or different from each other and each represents hydrogen or lower alkyl, and n represents an integer of 1 to 4.

  一种可用作免疫抑制剂的新型四环化合物，由通式（I）表示，或其药理上可接受的盐 其中 X¹ 和 X² 可以相同或不同，各自代表氢或低级烷基，n 代表 1 至 4 的整数。
• Structure–activity relationships of novel piperazines as antagonists for the melanocortin-4 receptor
  作者：Dai Nozawa、Taketoshi Okubo、Takaaki Ishii、Hiroyuki Kakinuma、Shigeyuki Chaki、Shigeru Okuyama、Atsuro Nakazato

  DOI：10.1016/j.bmc.2006.12.039

  日期：2007.3

  During the investigation of antagonists for the MC4 receptor, we found that 10ab having a naphthyl group showed almost the same binding affinity for the MC4 receptor as that of the lead compound I with a benzoyl group. We also developed a new type of compounds.. namely, bis-piperazines, and found that the bis-piperazines 10 exhibited a high affinity for the MC4 receptor. In particular, (-)-10bg exhibited the highest affinity for the MC4 receptor with an IC50 value of 8.13 nM. In this paper, we present the design, synthesis, and structure-activity relationships of the novel bis-piperazines as MC4 receptor antagonists. (c) 2007 Elsevier Ltd. All rights reserved.